Skip to main content
A

ADALTA LIMITED — Investor Relations & Filings

Ticker · 1AD ISIN · AU0000001AD2 LEI · 254900XT3BQIT6GR6M94 ASX Professional, scientific and technical activities
Open in API
Filings indexed 711 across all filing types
Latest filing 2026-04-20 Regulatory Filings
Country AU Australia
Listing ASX 1AD

About ADALTA LIMITED

https://adalta.com.au/

AdAlta Limited is a clinical-stage biotechnology company focused on the discovery and development of a new class of protein therapeutics called i-bodies. The company utilizes its proprietary i-body platform to engineer highly stable, small-format proteins that mimic the binding characteristics of shark antibodies. These i-bodies are designed to target complex disease-related proteins that are often inaccessible to traditional monoclonal antibodies. AdAlta's lead therapeutic candidate, AD-214, is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic conditions. The platform's versatility allows for the creation of diverse therapeutic leads across multiple disease areas, including inflammation and oncology, by leveraging the unique structural properties of the human protein scaffold-based i-body library.

Recent filings

Filing Released Lang Actions
Automated cell therapy manufacturing MoU 4 pages 271.4KB
Regulatory Filings Classification · 1% confidence The document is an ASX announcement detailing a Memorandum of Understanding (MoU) for a collaboration and technology deployment. It is not a full financial report, annual/quarterly report, earnings release, proxy statement, capital change, or management change notice. It is a general regulatory announcement (press release) to the exchange, which falls under the fallback “Regulatory Filings (RNS)” category.
2026-04-20 English
Board Change and Appendix 3Z 4 pages 453.1KB
Board/Management Information Classification · 1% confidence The document is an ASX announcement announcing the retirement of a Non-Executive Director and changes to the Board. It primarily communicates a board change (Non-Executive Director Dr David Fuller retiring) and includes a notice pursuant to listing rules, which supports a board/management update. This aligns with the “Board/Management Information” category (MANG).
2026-04-16 English
Notification of cessation of securities - 1AD 4 pages 14.8KB
Regulatory Filings
2026-04-01 English
BZDS1901 clinical update 4 pages 400.9KB
Regulatory Filings
2026-03-31 English
AdCella and SHcell hold first JDC meeting 3 pages 397.8KB
Regulatory Filings
2026-03-26 English
New AD-214 patent granted 2 pages 238.7KB
Regulatory Filings
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.